Phase 1 Trial of GPC2-Directed Chimeric Antigen Receptor Autologous T Cells (GPC2 CAR T) for Relapsed or Refractory Neuroblastoma
Latest Information Update: 27 Sep 2024
Price :
$35 *
At a glance
- Drugs GPC2 CAR T cell therapy Childrens Hospital of Philadelphia Tmunity Therapeutics (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions; First in man
- 23 May 2023 Status changed from not yet recruiting to recruiting.
- 17 Mar 2023 Planned initiation date changed from 30 Apr 2023 to 30 Oct 2023.
- 13 Feb 2023 Planned initiation date changed from 30 Jan 2023 to 30 Apr 2023.